Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16400185 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TSHRENPP2HCRTR1HCRTR2 | |
| SCHEMBL17069030 | 0.82 | ALDH1A1 (0.67) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL16945633 | 0.81 | SPHK2 (0.41) | ALDH1A1ENPP2HCRTR1HCRTR2 | |
| SCHEMBL3369475 | 0.77 | HCRTR1 (0.61) | TSHRHCRTR1HCRTR2DPP4 | |
| SCHEMBL17069039 | 0.77 | HCRTR1 (0.41) | ALDH1A1TSHRHCRTR1HCRTR2MAPT | |
| SCHEMBL16945609 | 0.76 | CHRM2 (0.47) | — | |
| SCHEMBL2600232 | 0.75 | HSD11B1 (0.55) | ALDH1A1TSHRENPP2KMT2AMAPT | |
| SCHEMBL17069015 | 0.75 | HCRTR1 (0.46) | ENPP2HCRTR1HCRTR2 | |
| SCHEMBL17243814 | 0.74 | ALDH1A1 (0.38) | ALDH1A1TSHRENPP2HCRTR1HCRTR2 | |
| SCHEMBL17069036 | 0.74 | HCRTR1 (0.41) | HCRTR1HCRTR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | ALDH1A1 1086/4885TSHR 181/4885ENPP2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.